Lucile Xerri-Astorgues

Lamorlaye, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma.

Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma.

Journal: The Journal of pathology

Published: April 18, 2022

Microbiome and pancreatic ductal adenocarcinoma.

Microbiome and pancreatic ductal adenocarcinoma.

Journal: Clinics and research in hepatology and gastroenterology

Published: October 31, 2020

Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models.

Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models.

Journal: Leukemia & lymphoma

Published: June 18, 2019

Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy.

Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy.

Journal: Oral oncology

Published: July 20, 2018

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.

Journal: Oncotarget

Published: July 25, 2016

Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.

Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.

Journal: International journal of cancer

Published: May 11, 2016

OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.

OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.

Journal: International journal of cancer

Published: February 02, 2016

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.

Journal: Oncotarget

Published: January 21, 2016

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 25, 2015

Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors.

Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors.

Journal: Biochimie

Published: September 06, 2014

OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis.

OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 11, 2014

Unraveling galectin-1 as a novel therapeutic target for cancer.

Unraveling galectin-1 as a novel therapeutic target for cancer.

Journal: Cancer treatment reviews

Published: May 06, 2013

Showing 1-12 of 14

Last Updated: 09/26/2026